PSID EXCERPT; QT could have big winner here; PositiveID Corporation
OTCBB: PSID – $.0311 per share)
www.PositiveIDCorp.com
PSID - Recent Investor Presentation
Industry: Biotechnology / Defense
Common Shares Outstanding / 111M
Market Cap / $3.45M
52-Week High / $.298 52-Week Low / $.0281
Average Price / .0464 (50-day) .1222 (200-day)
Average Volume / 553,128 (50-day) 388,613 (200-day)
New Businessweek Article: PositiveID and Northrop Grumman Named Top Candidates to Win $3.1 Billion Contract; Bidding on Contract Urged to Begin by October
Commercial Launch of Recently FDA Cleared Device iglucose™Expected in Q3
Global Market for Glucometers and Strips Forecasted to Reach $18 Billion by 2015
PSID is designated as a Bulletin Board listed stock and is current on all its financial filings. PSID is actively traded with the 50-day average daily volume at over 500,000 shares per day. The spread on PSID is typically very tight and there are over 15 market makers displayed on both sides of the market.
PSID hit a high of .298 per share when iglucose™ was cleared by the FDA.
PositiveID Corporation develops molecular diagnostic systems focused on airborne bio-threat detection and rapid medical testing, and unique medical devices focused on diabetes management. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
Businessweek Article Identifies $3.1 Billion Contract; PositiveID and Northrop Grumman Named as Top Potential Candidates to Win Contract - In an article dated June 21, 2012 in Bloomberg Businessweek The Sky-High Price of Sniffing Out Anthrax, it states, “Now that PositiveID and Northrop Grumman say they’ve worked through these problems, Homeland Security wants to open bidding on a $3.1 billion contract for the labs-in-a-box before October.” Businessweek Article dated 06-21-12. Total estimates to buy and maintain new sensors have surged to $5.7 billion.
One of Two Known Players for Major Government Contract - PositiveID’s M-Band Molecular Diagnostic System is one of only two known devices that can fill the U.S. government’s need for automatic detection of airborne bio-threats. We cannot stress enough how big the potential is here. If PositiveID is chosen for the award, the underlying stock of PSID could shoot to well over $1 per share.
Dragonfly - PositiveID's MicroFluidic Systems division has developed a series of microfluidic cartridges for biological sample processing and detection. Examples include differential extraction cartridges, sample processing and amplification for biodefense applications, and clinical sample processing and detection. The microfluidic cartridge approach has many distinct advantages that include: low cost, disposable, easy to use, prevents sample to sample contamination, fast results, portable, automated, and prevents human error.
FDA Clears iglucose™ - PositiveID received clearance from the U.S. Food and Drug Administration ("FDA") for its iglucose™ mobile health system for diabetes management last November, and will commercially launch the product this quarter. iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. This makes it possible to improve care in a cost-effective manner and help loved ones manage their diabetes.
More Products in Diabetes Management – PositiveID is actively developing other products for the massive diabetes management market. Currently under development in Israel, Easy Check is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. Also, the GlucoChip is a bio-sensor system that is essentially an implantable, bio-sensing RFID microchip that measures glucose levels in the body in real time.
